TNFRSF9 and head and neck squamous cell carcinoma: Results of safety analysis of the agonist of the CD137 mAb, urelumab, which included 10 patients with HNSCC showed favorable safety profile as well as pharmacodynamic activity by inducing IFN-inducible genes and cytokines [50].